Ricardo Menegatti | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Ricardo Menegatti | Pharmaceutical Science | Best Researcher Award

Associate Professor and UFG, Brazil

Assoc. Prof. Dr. Ricardo Menegatti is an Associate Professor at the Faculty of Pharmacy, Federal University of Goiás (UFG), Brazil. His academic journey began with a Bachelor’s degree in Pharmacy from the Federal University of Santa Catarina (UFSC), followed by a Master’s degree in Chemistry and a Ph.D. in Chemistry from the Federal University of Rio de Janeiro (UFRJ). His doctoral research focused on the design, synthesis, and pharmacological evaluation of novel neuroactive drug prototypes. Dr. Menegatti’s expertise spans various aspects of medicinal chemistry, including the development of new pharmacological agents, medicinal chemistry, and pharmaceutical analysis. He has been actively involved in teaching and research since joining UFG in 2006, where he has contributed to the development of courses in medicinal chemistry, pharmaceutical analysis, and organic chemistry. His work also includes extensive contributions to the university’s extension activities, such as coordinating workshops and seminars on pharmaceutical chemistry. Dr. Menegatti has a robust record of publications and presentations in his field, and his research interests primarily revolve around the synthesis of novel pharmacological agents and the application of advanced chemical techniques in drug development.

Profile
Education

Dr. Ricardo Menegatti holds a distinguished educational background in the field of pharmacy and chemistry. He earned his Bachelor’s degree in Pharmacy from the Federal University of Santa Catarina (UFSC) in 1998, where his research focused on leprosy. He then pursued advanced studies at the Federal University of Rio de Janeiro (UFRJ), obtaining a Master’s degree in Chemistry in 2001. His master’s research, under the guidance of Eliezer Jesus Barreiro, involved the design, synthesis, and pharmacological evaluation of new antipsychotic drug candidates, specifically targeting schizophrenia. Dr. Menegatti further advanced his expertise by completing a Ph.D. in Chemistry at UFRJ in 2005, focusing on the planning, synthesis, and pharmacological assessment of neuroactive drug prototypes, particularly in the areas of GABA, hypnotics, and analgesics. His doctoral research, also mentored by Eliezer J. Barreiro, was supported by the National Council for Scientific and Technological Development (CNPq), reflecting his commitment to advancing pharmaceutical sciences.

Professional Experience

Dr. Ricardo Menegatti is a seasoned academic and researcher with a strong background in pharmaceutical chemistry and medicinal compounds. He holds a Doctorate in Chemistry from the Federal University of Rio de Janeiro, where his research focused on the design, synthesis, and pharmacological evaluation of neuroactive drug prototypes. Dr. Menegatti currently serves as a Professor at the Faculty of Pharmacy, Federal University of Goiás, Brazil, where he has been a dedicated faculty member since 2006. His expertise lies in planning and synthesizing biologically active compounds, particularly those targeting neuroactive and antipsychotic pathways. In addition to his teaching responsibilities, Dr. Menegatti is actively involved in graduate-level mentoring, guiding students in the Biological Sciences postgraduate program. His contributions extend to organizing workshops, coordinating seminars, and participating in extension activities, reflecting his commitment to advancing pharmaceutical education and research.

Research Interests

Dr. Ricardo Menegatti’s research interests lie at the intersection of pharmaceutical chemistry and medicinal chemistry, with a particular focus on the design, synthesis, and pharmacological evaluation of biologically active compounds. His work primarily revolves around the development of neuroactive drug prototypes, targeting the GABAergic system to explore potential treatments for neurological disorders such as schizophrenia, anxiety, and sleep disorders. Additionally, Dr. Menegatti is engaged in the discovery of new analgesic and antipsychotic agents, leveraging his expertise in molecular modeling and structure-activity relationships (SAR) to enhance drug efficacy and safety. His research also extends to the use of solid-phase synthesis and enzymatic catalysis in drug development, aiming to innovate in the creation of new therapeutic agents. Through his work, Dr. Menegatti contributes to the advancement of medicinal chemistry, striving to address critical challenges in the treatment of mental health disorders.

Awards and Recognition

Dr. Menegatti’s academic and research excellence has been recognized through various awards and honors throughout his career. As a recipient of scholarships from the National Council for Scientific and Technological Development (CNPq) in Brazil, he has demonstrated a strong commitment to advancing scientific knowledge. His leadership in organizing workshops and seminars further highlights his contributions to the academic community, earning him recognition among his peers and students.

Conclusion

Dr. Ricardo Menegatti’s extensive research contributions in medicinal chemistry, particularly in the development of neuroactive and antipsychotic drug candidates, make him a strong candidate for the Research for Best Researcher Award. His work has a significant geographic impact, with potential applications in global healthcare. While his research is primarily focused on pharmaceutical sciences, its implications extend to broader areas such as infectious diseases. Dr. Menegatti’s collaborative efforts, applied research, and academic leadership further solidify his suitability for this prestigious award.

Publications Top Notes

LQFM289: Electrochemical and Computational Studies of a New Trimetozine Analogue for Anxiety Treatment

  • Journal: International Journal of Molecular Sciences
  • Date: September 26, 2023
  • DOI: 10.3390/ijms241914575

Bioanalytical LC-QTOF/MS Method for a N-phenylpiperazine Derivate (LQFM05): An Anxiolytic- and Antidepressant-like Prototype Drug Applied to Pharmacokinetic and Biodistribution Studies

Antileishmanial Activity of the Chalcone Derivative LQFM064 Associated with Reduced Fluidity in the Parasite Membrane as Assessed by EPR Spectroscopy

Toxico-Pharmacological Evaluations of the Small-Molecule LQFM166: Inducer of Apoptosis and MDM2 Antagonist

 

Assist Prof Dr. Omaish Alqahtani | Pharmacognosy

Posted on by ScienceFather
🎉🏆 Congratulations,Assist Prof Dr. Omaish Alqahtani, on Your Outstanding Achievement as the Best Researcher! 🏆🎉
Assist Prof Dr. Omaish  Alqahtani : Leading Researcher in Pharmacognosy

Congratulations, Prof Dr. Omaish  Alqahtani, on winning the esteemed Best Researcher Award from Sciencefather! Your dedication, innovative research, and scholarly contributions have truly made a significant impact in your field. Your commitment to advancing knowledge and pushing the boundaries of research is commendable. Here’s to your continued success in shaping the future of academia and making invaluable contributions to your field. Well done!

Assist Prof Dr. Omaish Alqahtani, a distinguished academic and researcher in the field of renewable energy, holds a Assistant professor in Pharmacognosy from Najran University, Saudi Arabia. His academic journey has been marked by a profound dedication to advancing solar energy technologies, specifically in solar thermal harvesting and its integration into agricultural and architectural applications.

Professional Experiences

❖ Assistant Professor (2022 – present)

  • College of Pharmacy, Najran University, Najran, Saudi Arabia

❖ Lecturer (2017 – 2022)

  • College of Pharmacy, Najran University, Najran, Saudi Arabia

❖ Teaching Assistant (2011 – 2017)

  • College of Pharmacy, Najran University, Najran, Saudi Arabia

❖ Pharmacist (10/2010 – 1/2011)

  • King Fahad Central Hospital, Jazan, Saudi Arabia

Committee Memberships

❖ Head of the Teaching and Learning Unit (2022 – present)

❖ Head of the E-Learning Unit (2022 – present)

❖ Member of the Annual Report Committee (2022 – present)

❖ Member of the Field Training and Alumni Unit (2021 – present)

❖ Head of the Training and Scholarship Unit (2021 – 2023)

❖ Member of the Scientific Research Unit (2021 – 2023)

❖ Member of the Student Activities Unit (2022 – 2023)

Teaching Experiences

  • Recent Approaches in Medicinal plants analysis.
  • Herbal and Alternative Medicine.
  • Pharmacognosy (2).
  • Pharmacognosy (1) – Practical.

Education

❖ PhD in Pharmacognosy (2021)

  • School of Pharmacy, University College London, London, United Kingdom.

❖ MSc in Pharmacognosy (2015)

  • School of Pharmacy, University College London, London, United Kingdom.

❖ BSc in Pharmaceutical Sciences (2010)

  • College of Pharmacy, King Khalid University, Abha, Saudi Arabia.

Scientific Societies

❖ Member of the American Society of Pharmacognosy.

❖ Member of the Society of Medicinal Plant and Natural Products.

❖ Member of the Phytochemical Society of Europe.

Research Interest

❖ Discovering novel bioactive compounds from plants and bacteria.

Research List

  1. Design, Characterization, and Antimicrobial Evaluation of Copper Nanoparticles Utilizing Tamarixinin, an Ellagitannin from Galls of Tamarix aphylla.
  2. Phytochemistry, anti-diabetic and antioxidant potentials of Allium consanguineum Kunth.
  3. Synergistic Effect between Amoxicillin and Zinc Oxide Nanoparticles Reduced by Oak Gall Extract Against Helicobacter pylori.
  4. In Vitro Antibacterial Activity of Green Synthesized Silver Nanoparticles Using Azadirachta indica Aqueous Leaf Extract against MDR Pathogens.
  5. Characterization and isolation of the major biologically active metabolites isolated from Ficus retusa and their synergistic effect with Tetracycline against certain pathogenic-resistant Bacteria.
  6. The Biosynthesized Zinc Oxide Nanoparticles’ Antiviral Activity in Combination with Pelargonium zonale Extract against the Human Corona 229E Virus.
  7. Human Lung Cancer (A549) Cell Line Cytotoxicity and Anti-Leishmania major Activity of Carissa macrocarpa Leaves: A Study Supported by UPLCESI-MS/MS Metabolites Profiling and Molecular Docking.
  8. Phytochemical fingerprint and biological activities of three Malaysian Ficus Deltoidea Cultivars.
  9. Production of antibacterial compounds using Bacillus spp. isolated from thermal springs in Saudi Arabia.
  10. Quantitative-HPLC-DAD polyphenols analysis, anxiolytic and cognition enhancing potentials of Sorbaria tomentosa Lindl. Rehder.
  11. Process optimization, antioxidant, antibacterial, drug adjuvant properties of bioactive keratin microparticles derived from porcupine (Hystrix indica) quills.
  12. Nutritional, Antioxidant, Antimicrobial, and Anticholinesterase Properties of Phyllanthus emblica: A Study Supported by Spectroscopic and Computational Investigations.